ClinConnect ClinConnect Logo
Search / Trial NCT06431555

Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome

Launched by BEIJING CHAO YANG HOSPITAL · May 22, 2024

Trial Information

Current as of November 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new way to look at lung function in patients with a condition called Combined Pulmonary Fibrosis and Emphysema Syndrome (CPFE). Researchers are using a special type of imaging called magnetic resonance imaging (MRI) to see how blood flow in the lungs changes over time. By examining patients at the start of the study, and again after 6 and 12 months, the team hopes to find early signs of lung problems that could help with diagnosis and treatment.

To participate in this trial, individuals need to meet certain criteria. They should have imaging results showing emphysema primarily in the upper lungs and pulmonary fibrosis in the lower lungs. Those interested should also be able to undergo an MRI without any issues, like having a pacemaker or feeling claustrophobic. Participants will undergo MRI scans at the designated times, and their experiences will help researchers learn more about how these lung diseases progress. This study is currently recruiting patients of all ages and genders who meet the eligibility criteria.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • (1) Chest HRCT shows emphysema mainly distributed in the upper lung field, manifesting as wallless or thin-walled (wall thickness \<1 mm) low-transmittance areas with clear boundaries with normal tissue, or multiple bullae (diameter \> 1 cm), and the emphysema area/total lung volume is ≥10%; (2) interstitial pulmonary fibrosis mainly distributed in the lower lung field and subpleura, manifesting as honeycomb shadow or grid shadow, and the lung structure is destroyed , may be accompanied by traction bronchiectasis, ground glass opacities and consolidation opacities.
  • Exclusion Criteria:
  • (1) Refusal to sign the informed consent form; (2) MRI contraindications (implanted pacemaker/defibrillator, claustrophobia, or any clinical condition that prohibits longer MRI examinations).

About Beijing Chao Yang Hospital

Beijing Chao Yang Hospital, a leading medical institution in China, is dedicated to advancing healthcare through innovative clinical research and trials. Affiliated with the Capital Medical University, the hospital boasts a multidisciplinary team of experienced healthcare professionals and researchers committed to improving patient outcomes. With a focus on evidence-based medicine, Beijing Chao Yang Hospital actively engages in diverse clinical studies across various therapeutic areas, aiming to contribute to the global medical community and enhance the standard of care through rigorous scientific inquiry.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Shumin Wang, PhD

Study Director

Beijing Chao Yang Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported